GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (STU:NVV1) » Definitions » Total Inventories

Novavax (STU:NVV1) Total Inventories : €14.5 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Novavax Total Inventories?

Novavax's total inventories for the quarter that ended in Mar. 2024 was €14.5 Mil. Novavax's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was €26.4 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Novavax's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was €-11.25.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Novavax's Days Inventory for the three months ended in Mar. 2024 was 44.18.

Inventory Turnover measures how fast the company turns over its inventory within a year. Novavax's Inventory Turnover for the quarter that ended in Mar. 2024 was 2.07.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Novavax's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.31.


Novavax Total Inventories Historical Data

The historical data trend for Novavax's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Total Inventories Chart

Novavax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 7.85 34.63 38.24

Novavax Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.93 21.68 65.21 38.24 14.52

Novavax Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Novavax  (STU:NVV1) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Novavax's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(442.139+0.75 * 19.67+0.5 * 14.516-2042.969
-0-0)/140.373
=-11.25

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Novavax's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=26.3755/54.473*365 / 4
=44.18

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Novavax's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=54.473 / 26.3755
=2.07

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Novavax's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=26.3755 / 86.347
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Novavax Total Inventories Related Terms

Thank you for viewing the detailed overview of Novavax's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax (STU:NVV1) Business Description

Traded in Other Exchanges
Address
21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Novavax (STU:NVV1) Headlines

No Headlines